Skip to main content

Day: May 9, 2024

VitalHub Corp. Reports First Quarter 2024 Financial Results

ARR up 21% YoY to $47.8 millionTotal Revenue up 21% to $15.3 millionEBITDA up 56% YoY to $3.1 million TORONTO, May 09, 2024 (GLOBE NEWSWIRE) — VitalHub Corp. (the “Company” or “VitalHub”) (TSX:VHI) (OTCQX:VHIBF) announced today it has filed its Interim Condensed Consolidated Financial Statements and Management’s Discussion and Analysis report for the three ended March 31, 2024, with the Canadian securities authorities. These documents may be viewed under the Company’s profile at www.sedar.com. Dan Matlow, CEO of VitalHub, commented on the quarter’s success, stating, “We are thrilled to report that VitalHub has kicked off 2024 with outstanding momentum, achieving a 21% increase in revenue, which rose to $15.3 million, up from $12.6 million in Q1 last year. Our focus on driving operational excellence and expanding our solution...

Continue reading

NeOnc Technologies Invited to Present at California Investment Forum in Anaheim on May 10

SoCal-based Clinical-Stage Biopharmaceutical Company Focused on Novel Therapeutics for Brain and Central Nervous System Diseases Nominated for Breakthrough Medical Technology Achievement Award LOS ANGELES, May 09, 2024 (GLOBE NEWSWIRE) — NeOnc Technologies Holdings, Inc., a clinical stage biopharmaceutical company, is proud to be presenting at the 2024 California Investment Forum (CIF), which will take place May 8-11 at the Anaheim Majestic Garden Hotel in Anaheim, California. The CIF has recognized NeOnc’s contributions to medical technology by nominating it for the prestigious Breakthrough Medical Technology Achievement Award to be presented by Treasurer Ma. The forum will feature groundbreaking companies from over 15 countries, providing unparalleled access to a network of investors and partners dedicated to fostering innovative...

Continue reading

Savanna Provides Update on Qualifying Transaction

Not for distribution to United States newswire services or for release publication, distribution or dissemination directly, or indirectly, in whole or in part, in or into the United States. TORONTO, May 09, 2024 (GLOBE NEWSWIRE) — SAVANNA CAPITAL CORP. (“Savanna” or the “Company”) (TSX-V: SAC.P), a capital pool company as defined under Policy 2.4 – Capital Pool Companies (the “CPC Policy”) of the TSX Venture Exchange (the “Exchange”), provides an update to its press release dated March 4, 2022 and November 9, 2022 (the “Press Releases”) whereby Savanna announced that it had entered into a definitive agreement dated March 1, 2022 (the “Definitive Agreement”) with 1000090242 Ontario Inc., a privately held corporation existing under the laws of the Province of Ontario (“San Luis ON”), relating to the proposed business combination...

Continue reading

Intermap Announces 42% Revenue Growth in the First Quarter

Recurring revenue represented 51% of total revenue and 72% of commercial revenue First payments have been received for the Indonesian mapping program Affirming 2024 projections of $16-18 million in revenue with EBITDA margin of approximately 25% DENVER, May 09, 2024 (GLOBE NEWSWIRE) — Intermap Technologies (TSX: IMP; OTCQB: ITMSF) (“Intermap” or the “Company”), a global leader in 3D geospatial products and intelligence solutions, today announced 42% revenue growth in the first quarter of 2024. For the period ending March 31, 2024, the Company reported revenue of $1.7 million, compared with $1.2 million for the fourth quarter of 2023. Additionally, deferred revenue increased by $2.6 million, driven primarily by the receipt of initial payments from the Indonesian government. Adjusted for upfront payments, which were invested to...

Continue reading

Phio Pharmaceuticals Reports Q1 2024 Results and Provides Business Update

–Four sites across the country participating in Phase 1b clinical trial for lead product candidate PH-762 –Three patients have been enrolled MARLBOROUGH, Mass., May 09, 2024 (GLOBE NEWSWIRE) — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today reported its Q1 2024 financial results and provided a business update. Recent Corporate UpdatesPhio’s INTASYL compound PH-762 is currently being investigated in an open-label Phase 1b clinical study (NCT 06014086) to evaluate the safety and tolerability of intratumoral PH-762 in cutaneous squamous cell (cSCC), melanoma, or Merkel cell carcinoma. Two patients have already completed treatment. Four sites across the...

Continue reading

The Keg Royalties Income Fund Announces First Quarter 2024 Results

Not for distribution to U.S. News wire services or dissemination in the U.S. VANCOUVER, British Columbia, May 09, 2024 (GLOBE NEWSWIRE) — The Keg Royalties Income Fund (the “Fund”) (TSX: KEG.UN) is pleased to announce its financial results for the three months ended March 31, 2024 (the “quarter”). HIGHLIGHTSRoyalty Pool Sales(1) of $181.2M, down 5.5% for the quarter KRL Average Sales per Operating Week(1) of $134,000 per Operating Week, down 4.3% for the quarter Same Store Sales(1) down 5.1% for the quarter Distributable Cash(1) up 20.4% to $0.410/Fund unit for the quarter Special cash distribution of $0.08/Fund unit paid on January 31, 2024 Payout Ratio(2) was 69.3% for the quarterRoyalty Pool Sales reported by the 105 Keg restaurants in the Royalty Pool were $181,249,000 for the quarter, a decrease of $10,625,000 or 5.5%...

Continue reading

Mercer International Inc. Reports First Quarter 2024 Results and Announces Quarterly Cash Dividend Of $0.075

Selected HighlightsFirst quarter Operating EBITDA* of $63.6 million and net loss of $16.7 millionImproving pulp markets and lower costs driving stronger EBITDAQuarterly cash dividend of $0.075 per shareNEW YORK, May 09, 2024 (GLOBE NEWSWIRE) — Mercer International Inc. (Nasdaq: MERC) today reported first quarter 2024 Operating EBITDA of $63.6 million, an increase from $27.5 million in the same quarter of 2023 and $21.1 million in the fourth quarter of 2023. In the first quarter of 2024, net loss was $16.7 million (or $0.25 per share), which included a non-cash loss on disposal of $23.6 million (or $0.35 per share) relating to the dissolution of the Cariboo Pulp and Paper (“CPP”) joint venture, compared to a net loss of $30.6 million (or $0.46 per share) in the first quarter of 2023 and a net loss of $87.2...

Continue reading

Kinross announces Annual Shareholder Meeting voting results

TORONTO, May 09, 2024 (GLOBE NEWSWIRE) — Kinross Gold Corporation (TSX: K, NYSE: KGC) has announced the detailed voting results of the election of its Board of Directors, which took place at the Company’s virtual Annual Meeting of Shareholders on May 8, 2024. The nominees listed in the Management Information Circular dated March 12, 2024, were elected as directors of Kinross at the meeting (see detailed voting results below). Board of Directors voting resultsNominee Votes for % for Votes withheld % withheldKerry D. Dyte 763,966,358 95.76% 33,838,456 4.24%Glenn A. Ives 790,145,889 99.04% 7,658,922 0.96%Ave G. Lethbridge 773,109,953 96.90% 24,694,858 3.10%Michael A. Lewis 789,269,572 98.93% 8,535,239 1.07%Elizabeth D. McGregor 796,309,472 99.81% 1,495,338 0.19%Catherine McLeod-Seltzer 681,020,185 85.36% 116,784,572 14.64%Kelly...

Continue reading

Associated Capital Group, Inc. Reports Increased First Quarter Book Value

 AUM: $1.55 billion at March 31, 2024 compared to $1.59 billion at December 31, 2023 Book Value per share ended the quarter at $42.80 per share vs $42.11 at December 31, 2023GREENWICH, Conn., May 09, 2024 (GLOBE NEWSWIRE) — Associated Capital Group, Inc. (“AC” or the “Company”), a diversified financial services company, today reported its financial results for the first quarter ended March 31, 2024. Financial Highlights ($ in 000’s except AUM and per share data)(Unaudited)   Three Months Ended March 31,      2024     2023  AUM – end of period (in millions)   $ 1,549     $ 1,799  AUM – average (in millions)     1,556       1,841                   Revenues     3,011       2,465  Operating loss before management fee (Non-GAAP)     (2,988 )     (2,590 )Investment and other non-operating...

Continue reading

Interfor Reports Q1’24 Results

Adjusted EBITDA loss of $22 million and Net Loss of $73 million BURNABY, British Columbia, May 09, 2024 (GLOBE NEWSWIRE) — INTERFOR CORPORATION (“Interfor” or the “Company”) (TSX: IFP) recorded a Net loss in Q1’24 of $72.9 million, or $1.42 per share, compared to a Net loss of $169.0 million, or $3.29 per share in Q4’23 and a Net loss of $41.3 million, or $0.80 per share in Q1’23. Adjusted EBITDA was a loss of $22.3 million on sales of $813.2 million in Q1’24 versus a loss of $51.4 million on sales of $785.9 million in Q4’23 and Adjusted EBITDA of $26.1 million on sales of $829.9 million in Q1’23. Notable items:Ongoing Weak Lumber MarketLumber prices continued to reflect an imbalance of lumber supply and demand, with demand continuing to be impacted by the elevated interest rate environment and ongoing economic uncertainty....

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.